Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Osteoporosis International
Published in: Osteoporosis International 5/2017

01-05-2017 | Review

Mind the (treatment) gap: a global perspective on current and future strategies for prevention of fragility fractures

Authors: N. C. W. Harvey, E. V. McCloskey, P. J. Mitchell, B. Dawson-Hughes, D. D. Pierroz, J.-Y. Reginster, R. Rizzoli, C. Cooper, J. A. Kanis

Published in: Osteoporosis International | Issue 5/2017

Login to get access

Abstract

This narrative review considers the key challenges facing healthcare professionals and policymakers responsible for providing care to populations in relation to bone health. These challenges broadly fall into four distinct themes: (1) case finding and management of individuals at high risk of fracture, (2) public awareness of osteoporosis and fragility fractures, (3) reimbursement and health system policy and (4) epidemiology of fracture in the developing world. Findings from cohort studies, randomised controlled trials, systematic reviews and meta-analyses, in addition to current clinical guidelines, position papers and national and international audits, are summarised, with the intention of providing a prioritised approach to delivery of optimal bone health for all. Systematic approaches to case-finding individuals who are at high risk of sustaining fragility fractures are described. These include strategies and models of care intended to improve case finding for individuals who have sustained fragility fractures, those undergoing treatment with medicines which have an adverse effect on bone health and people who have diseases, whereby bone loss and, consequently, fragility fractures are a common comorbidity. Approaches to deliver primary fracture prevention in a clinically effective and cost-effective manner are also explored. Public awareness of osteoporosis is low worldwide. If older people are to be more pro-active in the management of their bone health, that needs to change. Effective disease awareness campaigns have been implemented in some countries but need to be undertaken in many more. A major need exists to improve awareness of the risk that osteoporosis poses to individuals who have initiated treatment, with the intention of improving adherence in the long term. A multisector effort is also required to support patients and their clinicians to have meaningful discussions concerning the risk-benefit ratio of osteoporosis treatment. With regard to prioritisation of fragility fracture prevention in national policy, there is much to be done. In the developing world, robust epidemiological estimates of fracture incidence are required to inform policy development. As the aging of the baby boomer generation is upon us, this review provides a comprehensive analysis of how bone health can be improved worldwide for all.
Literature
1.
Kanis JA, McCloskey EV, Johansson H, Cooper C, Rizzoli R, Reginster JY, Scientific Advisory Board of the European Society for C, Economic Aspects of O, Osteoarthritis, the Committee of Scientific Advisors of the International Osteoporosis F (2013) European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int 24:23–57PubMedCrossRef
2.
Gallagher JC, Melton LJ, Riggs BL, Bergstrath E (1980) Epidemiology of fractures of the proximal femur in Rochester, Minnesota. Clin Orthop Relat Res 163–171
3.
Port L, Center J, Briffa NK, Nguyen T, Cumming R, Eisman J (2003) Osteoporotic fracture: missed opportunity for intervention. Osteoporos Int 14:780–784PubMedCrossRef
4.
McLellan A, Reid D, Forbes K, Reid R, Campbell C, Gregori A, Raby N, Simpson A (2004) Effectiveness of strategies for the secondary prevention of osteoporotic fractures in Scotland (CEPS 99/03). NHS Quality Improvement Scotland
5.
Edwards BJ, Bunta AD, Simonelli C, Bolander M, Fitzpatrick LA (2007) Prior fractures are common in patients with subsequent hip fractures. Clin Orthop Relat Res 461:226–230PubMed
6.
Klotzbuecher CM, Ross PD, Landsman PB, Abbott TA 3rd, Berger M (2000) Patients with prior fractures have an increased risk of future fractures: a summary of the literature and statistical synthesis. J Bone Miner Res Off J Am Soc Bone Miner Res 15:721–739CrossRef
7.
Kanis JA, Johnell O, De Laet C et al (2004) A meta-analysis of previous fracture and subsequent fracture risk. Bone 35:375–382PubMedCrossRef
8.
Akesson K, Mitchell PJ (2012) Capture the Fracture: a global campaign to break the fragility fracture cycle. In: Stenmark J, Misteli L (eds) World Osteoporosis Day Thematic Report. International Osteoporosis Foundation, Nyon
9.
Kanis JA, Harvey NC, Cooper C, Johansson H, Odén A, McCloskey EV, the Advisory Board of the National Osteoporosis Guideline Group (2016) A systematic review of intervention thresholds based on FRAX: a report prepared for the National Osteoporosis Guideline Group and the International Osteoporosis Foundation. Arch Osteoporos accepted June, proofs July 2016
10.
Johnell O, Kanis JA, Oden A, Sernbo I, Redlund-Johnell I, Petterson C, De Laet C, Jonsson B (2004) Fracture risk following an osteoporotic fracture. Osteoporos Int 15:175–179PubMedCrossRef
11.
Wells GA, Cranney A, Peterson J, Boucher M, Shea B, Robinson V, Coyle D, Tugwell P (2008) Alendronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women. Cochrane Database Syst Rev CD001155
12.
Wells GA, Cranney A, Peterson J, Boucher M, Shea B, Robinson V, Coyle D, Tugwell P (2008) Etidronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women. Cochrane Database Syst Rev CD003376
13.
Wells G, Cranney A, Peterson J, Boucher M, Shea B, Robinson V, Coyle D, Tugwell P (2008) Risedronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women. Cochrane Database Syst Rev CD004523
14.
Albergaria BH, Gomes Silva BN, Atallah ÁN, Fernandes Moça Trevisani V (2010) Intravenous zoledronate for postmenopausal osteoporosis (Protocol). Cochrane Database Syst Rev 1–8
15.
Bennett TG, Le Marshall K, Khan F, Wark JD, Brand C (2012) Denosumab for the treatment and prevention of postmenopausal osteoporosis (Protocol). Cochrane Database Syst Rev 1–10
16.
17.
Black DM, Steinbuch M, Palermo L, Dargent-Molina P, Lindsay R, Hoseyni MS, Johnell O (2001) An assessment tool for predicting fracture risk in postmenopausal women. Osteoporos Int 12:519–528PubMedCrossRef
18.
Doherty DA, Sanders KM, Kotowicz MA, Prince RL (2001) Lifetime and five-year age-specific risks of first and subsequent osteoporotic fractures in postmenopausal women. Osteoporos Int 12:16–23PubMedCrossRef
19.
Lyles KW, Colon-Emeric CS, Magaziner JS et al (2007) Zoledronic acid and clinical fractures and mortality after hip fracture. N Engl J Med 357:1799–1809PubMedCrossRef
20.
Eastell R, Black DM, Boonen S et al (2009) Effect of once-yearly zoledronic acid five milligrams on fracture risk and change in femoral neck bone mineral density. J Clin Endocrinol Metab 94:3215–3225PubMedPubMedCentralCrossRef
21.
Palacios S, Kalouche-Khalil L, Rizzoli R et al (2015) Treatment with denosumab reduces secondary fracture risk in women with postmenopausal osteoporosis. Climacteric 18:805–812PubMedCrossRef
22.
Ettinger B, Black DM, Mitlak BH et al (1999) Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) investigators. JAMA 282:637–645PubMedCrossRef
23.
Neer RM, Arnaud CD, Zanchetta JR et al (2001) Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 344:1434–1441PubMedCrossRef
24.
Meunier PJ, Roux C, Seeman E et al (2004) The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis. N Engl J Med 350:459–468PubMedCrossRef
25.
Roux C, Reginster JY, Fechtenbaum J et al (2006) Vertebral fracture risk reduction with strontium ranelate in women with postmenopausal osteoporosis is independent of baseline risk factors. J Bone Miner Res Off J Am Soc Bone Miner Res 21:536–542CrossRef
26.
Seeman E, DeVogelaer JP, Lorenc RS, Spector T, Brixen K, Vellas B, Balogh A, Stucki G, Meunier PJ, Reginster JY (2004) Strontium ranelate: the first anti-osteoporotic agent to reduce the risk of vertebral fracture in patients with lumbar osteopenia. IOF World Congress on Osteoporosis. Osteoporos Int, Rio de Janeiro, pp 507–509
27.
28.
British Orthopaedic Association, British Geriatrics Society (2007) The care of patients with fragility fracture. 2nd edn
29.
30.
31.
Hawkes D, Baxter J, Bailey C, Holland G, Ruddlesdin J, Wall A, Wykes P (2015) Improving the care of patients with a hip fracture: a quality improvement report. BMJ Qual Saf 24:532–538PubMedCrossRef
32.
Royal College of Physicians (2015) National Hip Fracture Database (NHFD) annual report 2015. London
33.
Ganda K, Puech M, Chen JS, Speerin R, Bleasel J, Center JR, Eisman JA, March L, Seibel MJ (2013) Models of care for the secondary prevention of osteoporotic fractures: a systematic review and meta-analysis. Osteoporos Int 24:393–406PubMedCrossRef
34.
National Institute for Health and Clinical Excellence (2005) Bisphosphonates (alendronate, etidronate, risedronate), selective oestrogen receptor modulators (raloxifene) and parathyroid hormone (teriparatide) for the secondary prevention of osteoporotic fragility fractures in postmenopausal women. Technology appraisal guidance 87
35.
Bolland MJ, Grey AB, Gamble GD, Reid IR (2010) Effect of osteoporosis treatment on mortality: a meta-analysis. J Clin Endocrinol Metab 95:1174–1181PubMedCrossRef
36.
Huntjens KM, van Geel TA, van den Bergh JP, van Helden S, Willems P, Winkens B, Eisman JA, Geusens PP, Brink PR (2014) Fracture liaison service: impact on subsequent nonvertebral fracture incidence and mortality. J Bone Joint Surg Am 96:e29PubMedCrossRef
37.
McLellan AR, Wolowacz SE, Zimovetz EA, Beard SM, Lock S, McCrink L, Adekunle F, Roberts D (2011) Fracture liaison services for the evaluation and management of patients with osteoporotic fracture: a cost-effectiveness evaluation based on data collected over 8 years of service provision. Osteoporos Int 22:2083–2098PubMedCrossRef
38.
Giles M, Van Der Kallen J, Parker V, Cooper K, Gill K, Ross L, McNeill S (2011) A team approach: implementing a model of care for preventing osteoporosis related fractures. Osteoporos Int 22:2321–2328PubMedCrossRef
39.
Bogoch ER, Elliot-Gibson V, Beaton DE, Jamal SA, Josse RG, Murray TM (2006) Effective initiation of osteoporosis diagnosis and treatment for patients with a fragility fracture in an orthopaedic environment. J Bone Joint Surg Am 88:25–34PubMed
40.
Blonk MC, Erdtsieck RJ, Wernekinck MG, Schoon EJ (2007) The fracture and osteoporosis clinic: 1-year results and 3-month compliance. Bone 40:1643–1649PubMedCrossRef
41.
Chevalley T, Hoffmeyer P, Bonjour JP, Rizzoli R (2002) An osteoporosis clinical pathway for the medical management of patients with low-trauma fracture. Osteoporos Int 13:450–455PubMedCrossRef
42.
Premaor MO, Pilbrow L, Tonkin C, Adams M, Parker RA, Compston J (2010) Low rates of treatment in postmenopausal women with a history of low trauma fractures: results of audit in a Fracture Liaison Service. QJM 103:33–40PubMedCrossRef
43.
McLellan AR, Gallacher SJ, Fraser M, McQuillian C (2003) The fracture liaison service: success of a program for the evaluation and management of patients with osteoporotic fracture. Osteoporos Int 14:1028–1034PubMedCrossRef
44.
Clunie G, Stephenson S (2008) Implementing and running a fracture liaison service: an integrated clinical service providing a comprehensive bone health assessment at the point of fracture management. J Orthop Nurs 12:156–162CrossRef
45.
Harrington JT, Barash HL, Day S, Lease J (2005) Redesigning the care of fragility fracture patients to improve osteoporosis management: a health care improvement project. Arthritis Rheum 53:198–204PubMedCrossRef
46.
Delmas PD, van de Langerijt L, Watts NB, Eastell R, Genant H, Grauer A, Cahall DL, Group IS (2005) Underdiagnosis of vertebral fractures is a worldwide problem: the IMPACT study. J Bone Miner Res Off J Am Soc Bone Miner Res 20:557–563CrossRef
47.
Imai N, Endo N, Hoshino T, Suda K, Miyasaka D, Ito T (2014) Mortality after hip fracture with vertebral compression fracture is poor. J Bone Miner Metab
48.
Sosa Henriquez M, Saavedra Santana P, grupo de trabajo en osteoporosis de la Sociedad Espanola de Medicina I (2007) Prevalence of vertebral fractures in hip fracture patients. Revista clinica espanola 207:464–468PubMedCrossRef
49.
Orimo H, Hayashi Y, Fukunaga M et al (2001) Gempatsusei kotusosyousyou no sindan kijun 2000 nendo kaitei ban (in Japanese). Nihon Kotsutaisya Gakkai Zasshi 14:76–82
50.
Genant HK, Wu CY, van Kuijk C, Nevitt MC (1993) Vertebral fracture assessment using a semiquantitative technique. J Bone Miner Res Off J Am Soc Bone Miner Res 8:1137–1148CrossRef
51.
Johansson H, Oden A, McCloskey EV, Kanis JA (2014) Mild morphometric vertebral fractures predict vertebral fractures but not non-vertebral fractures. Osteoporos Int 25:235–241PubMedCrossRef
52.
Mitchell PJ (2013) Best practices in secondary fracture prevention: fracture liaison services. Current osteoporosis reports 11:52–60PubMedCrossRef
53.
Gallacher SJ, Gallagher AP, McQuillian C, Mitchell PJ, Dixon T (2007) The prevalence of vertebral fracture amongst patients presenting with non-vertebral fractures. Osteoporos Int 18:185–192PubMedCrossRef
54.
Howat I, Carty D, Harrison J, Fraser M, McLellan AR (2007) Vertebral fracture assessment in patients presenting with incident nonvertebral fractures. Clin Endocrinol 67:923–930CrossRef
55.
Siris ES, Genant HK, Laster AJ, Chen P, Misurski DA, Krege JH (2007) Enhanced prediction of fracture risk combining vertebral fracture status and BMD. Osteoporos Int 18:761–770PubMedCrossRef
56.
57.
Osteoporosis Canada (2014) Quality Standards for Fracture Liaison Services in Canada. Osteoporosis Canada, Toronto
58.
Osteoporosis New Zealand (2016) Clinical Standards for Fracture Liaison Services in New Zealand. Osteoporosis New Zealand, Wellington
59.
British Orthopaedic Association, National Osteoporosis Society (2014) BOAST 9: Fracture Liaison Services. London
60.
Gittoes N, McLellan AR, Cooper A et al (2015) Effective secondary prevention of fragility fractures: clinical standards for fracture liaison services. National Osteoporosis Society, Camerton
61.
Akesson K, Marsh D, Mitchell PJ, McLellan AR, Stenmark J, Pierroz DD, Kyer C, Cooper C, IOF Fracture Working Group (2013) Capture the Fracture: a Best Practice Framework and global campaign to break the fragility fracture cycle. Osteoporos Int 24:2135–2152PubMedPubMedCentralCrossRef
62.
Javaid MK, Kyer C, Mitchell PJ et al (2015) Effective secondary fracture prevention: implementation of a global benchmarking of clinical quality using the IOF Capture the Fracture(R) Best Practice Framework tool. Osteoporos Int 26:2573–2578PubMedCrossRef
63.
64.
Mitchell PJ, Ganda K, Seibel MJ (2015) Australian and New Zealand bone and mineral society position paper on secondary fracture prevention programs. In press
65.
Department of Health (2009) Falls and fractures: effective interventions in health and social care. In Department of Health (ed)
66.
Osteoporosis New Zealand (2012) Bone Care 2020: a systematic approach to hip fracture care and prevention for New Zealand. Wellington
67.
Mitchell PJ, Cornish J, Milsom S, et al. (2014) BoneCare 2020: a systematic approach to hip fracture care and prevention for New Zealand. 3rd Fragility Fracture Network Congress 2014 Madrid, Spain
68.
van Staa TP, Dennison EM, Leufkens HG, Cooper C (2001) Epidemiology of fractures in England and Wales. Bone 29:517–522PubMedCrossRef
69.
Gauthier A, Kanis JA, Martin M, Compston J, Borgstrom F, Cooper C, McCloskey E, Committee of Scientific Advisors IOF (2011) Development and validation of a disease model for postmenopausal osteoporosis. Osteoporos Int 22:771–780PubMedCrossRef
70.
Cawston H, Maravic M, Fardellone P, Gauthier A, Kanis JA, Compston J, Borgstrom F, Cooper C, McCloskey E (2012) Epidemiological burden of postmenopausal osteoporosis in France from 2010 to 2020: estimations from a disease model. Arch Osteoporos 7:237–246PubMedCrossRef
71.
Gauthier A, Kanis JA, Jiang Y, Dreinhofer K, Martin M, Compston J, Borgstrom F, Cooper C, McCloskey E (2012) Burden of postmenopausal osteoporosis in Germany: estimations from a disease model. Arch Osteoporos 7:209–218PubMedCrossRef
72.
Piscitelli P, Brandi M, Cawston H, Gauthier A, Kanis JA, Compston J, Borgstrom F, Cooper C, McCloskey E (2014) Epidemiological burden of postmenopausal osteoporosis in Italy from 2010 to 2020: estimations from a disease model. Calcif Tissue Int 95:419–427PubMedCrossRef
73.
Gauthier A, Kanis JA, Jiang Y, Martin M, Compston JE, Borgström F, Cooper C, McCloskey EV (2011) Epidemiological burden of postmenopausal osteoporosis in the UK from 2010 to 2021: estimations from a disease model. Arch Osteoporos 6:179–188PubMedCrossRef
74.
Svedbom A, Hernlund E, Ivergard M, Compston J, Cooper C, Stenmark J, McCloskey EV, Jonsson B, Kanis JA, IOF EUrpot (2013) Osteoporosis in the European Union: a compendium of country-specific reports. Arch Osteoporos 8:137PubMedPubMedCentralCrossRef
75.
Hernlund E, Svedbom A, Ivergard M, Compston J, Cooper C, Stenmark J, McCloskey EV, Jonsson B, Kanis JA (2013) Osteoporosis in the European Union: medical management, epidemiology and economic burden: a report prepared in collaboration with the International Osteoporosis Foundation (IOF) and the European Federation of Pharmaceutical Industry Associations (EFPIA). Arch Osteoporos 8:136PubMedPubMedCentralCrossRef
76.
Ebeling PR (2014) Osteoporosis in men: why change needs to happen. In: Mitchell PJ (ed) World Osteoporosis Day Thematic Report. International Osteoporosis Foundation, Nyons
77.
Gerdhem P (2013) Osteoporosis and fragility fractures: vertebral fractures. Best Pract Res Clin Rheumatol 27:743–755PubMedCrossRef
78.
Bliuc D, Nguyen TV, Eisman JA, Center JR (2014) The impact of nonhip nonvertebral fractures in elderly women and men. J Clin Endocrinol Metab 99:415–423PubMedCrossRef
79.
Compston J, Bowring C, Cooper A et al (2013) Diagnosis and management of osteoporosis in postmenopausal women and older men in the UK: National Osteoporosis Guideline Group (NOGG) update 2013. Maturitas 75:392–396PubMedCrossRef
80.
Cosman F, de Beur SJ, LeBoff MS, Lewiecki EM, Tanner B, Randall S, Lindsay R, National Osteoporosis F (2014) Clinician’s guide to prevention and treatment of osteoporosis. Osteoporos Int 25:2359–2381PubMedPubMedCentralCrossRef
81.
Panday K, Gona A, Humphrey MB (2014) Medication-induced osteoporosis: screening and treatment strategies. Therapeutic advances in musculoskeletal disease 6:185–202PubMedPubMedCentralCrossRef
82.
83.
Tufano A, Coppola A, Contaldi P, Franchini M, Minno GD (2015) Oral anticoagulant drugs and the risk of osteoporosis: new anticoagulants better than old? Semin Thromb Hemost 41:382–388PubMedCrossRef
84.
Beerhorst K, van der Kruijs SJ, Verschuure P, Tan IY, Aldenkamp AP (2013) Bone disease during chronic antiepileptic drug therapy: general versus specific risk factors. J Neurol Sci 331:19–25PubMedCrossRef
85.
Rizzoli R, Body JJ, DeCensi A, Reginster JY, Piscitelli P, Brandi ML, European Society for C, Economical aspects of O, Osteoarthritis (2012) Guidance for the prevention of bone loss and fractures in postmenopausal women treated with aromatase inhibitors for breast cancer: an ESCEO position paper. Osteoporos Int 23:2567–2576PubMedCrossRef
86.
Lan GB, Xie XB, Peng LK, Liu L, Song L, Dai HL (2015) Current status of research on osteoporosis after solid organ transplantation: pathogenesis and management. Biomed Res Int 2015:413169PubMedPubMedCentral
87.
Whittier X, Saag KG (2016) Glucocorticoid-induced osteoporosis. Rheum Dis Clin N Am 42:177–189CrossRef
88.
Lopez LM, Grimes DA, Schulz KF, Curtis KM, Chen M (2014) Steroidal contraceptives: effect on bone fractures in women. The Cochrane database of systematic reviews 6:CD006033
89.
Lau AN, Tomizza M, Wong-Pack M, Papaioannou A, Adachi JD (2015) The relationship between long-term proton pump inhibitor therapy and skeletal frailty. Endocrine 49:606–610PubMedPubMedCentralCrossRef
90.
Rizzoli R, Cooper C, Reginster JY et al (2012) Antidepressant medications and osteoporosis. Bone 51:606–613PubMedCrossRef
91.
Palermo A, D’Onofrio L, Eastell R, Schwartz AV, Pozzilli P, Napoli N (2015) Oral anti-diabetic drugs and fracture risk, cut to the bone: safe or dangerous? A narrative review. Osteoporos Int 26:2073–2089PubMedCrossRef
92.
Canalis E, Mazziotti G, Giustina A, Bilezikian JP (2007) Glucocorticoid-induced osteoporosis: pathophysiology and therapy. Osteoporos Int 18:1319–1328PubMedCrossRef
93.
Albaum JM, Youn S, Levesque LE, Gershon AS, Cadarette SM (2014) Osteoporosis management among chronic glucocorticoid users: a systematic review. J Popul Ther Clin Pharmacol 21:e486–e504PubMed
94.
Lekamwasam S, Adachi JD, Agnusdei D et al (2012) A framework for the development of guidelines for the management of glucocorticoid-induced osteoporosis. Osteoporos Int 23:2257–2276PubMedCrossRef
95.
Newman ED, Matzko CK, Olenginski TP, Perruquet JL, Harrington TM, Maloney-Saxon G, Culp T, Wood GC (2006) Glucocorticoid-Induced Osteoporosis Program (GIOP): a novel, comprehensive, and highly successful care program with improved outcomes at 1 year. Osteoporos Int 17:1428–1434PubMedCrossRef
96.
97.
Zhumkhawala AA, Gleason JM, Cheetham TC, Niu F, Loo RK, Dell RM, Jacobsen SJ, Chien GW (2013) Osteoporosis management program decreases incidence of hip fracture in patients with prostate cancer receiving androgen deprivation therapy. Urology 81:1010–1015PubMedCrossRef
98.
99.
Coleman R, Body JJ, Aapro M, Hadji P, Herrstedt J, Group EGW (2014) Bone health in cancer patients: ESMO Clinical Practice Guidelines. Ann Oncol 25(Suppl 3):iii124–iii137PubMedCrossRef
100.
Damji AN, Bies K, Alibhai SM, Jones JM (2015) Bone health management in men undergoing ADT: examining enablers and barriers to care. Osteoporos Int 26:951–959PubMedCrossRef
101.
International Osteoporosis Foundation (2013) The Asia-Pacific regional audit: epidemiology, costs and burden of osteoporosis in 2013. Nyon, Switzerland
102.
Suarez-Almazor ME, Peddi P, Luo R, Nguyen HT, Elting LS (2014) Low rates of bone mineral density measurement in Medicare beneficiaries with prostate cancer initiating androgen deprivation therapy. Support Care Cancer 22:537–544PubMedCrossRef
103.
McGuire A, Brown JA, Malone C, McLaughlin R, Kerin MJ (2015) Effects of age on the detection and management of breast cancer. Cancers (Basel) 7:908–929CrossRef
104.
Dolan AL, Mohammed M, Thakur K (2007) Novel way to implement bone assessment guidelines to identify and manage patients receiving aromatase inhibitors using FITOS software. Osteoporos Int 18:S282–S283 Abstract P242A
105.
Spangler L, Yu O, Loggers E, Boudreau DM (2013) Bone mineral density screening among women with a history of breast cancer treated with aromatase inhibitors. J Women’s Health (Larchmt) 22:132–140CrossRef
106.
Giusti F, Ottanelli S, Masi L, Amedei A, Brandi ML, Falchetti A (2011) Construction of a database for the evaluation and the clinical management of patients with breast cancer treated with antiestrogens and/or aromatase inhibitors. Clinical cases in mineral and bone metabolism: the official journal of the Italian Society of Osteoporosis, Mineral Metabolism, and Skeletal Diseases 8:37–50
107.
International Diabetes Federation (2015) IDF diabetes atlas Seventh Edition. Brussels, Belgium
108.
109.
110.
111.
Alzheimer’s Disease International (2013) Policy brief for heads of government: the global impact of dementia 2013–2050. London, UK
112.
Cross M, Smith E, Hoy D et al (2014) The global burden of rheumatoid arthritis: estimates from the global burden of disease 2010 study. Ann Rheum Dis 73:1316–1322PubMedCrossRef
113.
Vestergaard P (2007) Discrepancies in bone mineral density and fracture risk in patients with type 1 and type 2 diabetes—a meta-analysis. Osteoporos Int 18:427–444PubMedCrossRef
114.
Janghorbani M, Van Dam RM, Willett WC, Hu FB (2007) Systematic review of type 1 and type 2 diabetes mellitus and risk of fracture. Am J Epidemiol 166:495–505PubMedCrossRef
115.
Graat-Verboom L, Wouters EF, Smeenk FW, van den Borne BE, Lunde R, Spruit MA (2009) Current status of research on osteoporosis in COPD: a systematic review. Eur Respir J 34:209–218PubMedCrossRef
116.
McEvoy CE, Ensrud KE, Bender E, Genant HK, Yu W, Griffith JM, Niewoehner DE (1998) Association between corticosteroid use and vertebral fractures in older men with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 157:704–709PubMedCrossRef
117.
West J, Logan RF, Card TR, Smith C, Hubbard R (2003) Fracture risk in people with celiac disease: a population-based cohort study. Gastroenterology 125:429–436PubMedCrossRef
118.
Bernstein CN, Blanchard JF, Leslie W, Wajda A, Yu BN (2000) The incidence of fracture among patients with inflammatory bowel disease. A population-based cohort study. Ann Intern Med 133:795–799PubMedCrossRef
119.
Baker NL, Cook MN, Arrighi HM, Bullock R (2011) Hip fracture risk and subsequent mortality among Alzheimer’s disease patients in the United Kingdom, 1988-2007. Age Ageing 40:49–54PubMedCrossRef
120.
van Staa TP, Geusens P, Bijlsma JW, Leufkens HG, Cooper C (2006) Clinical assessment of the long-term risk of fracture in patients with rheumatoid arthritis. Arthritis Rheum 54:3104–3112PubMedCrossRef
121.
Regan EA, Radcliff TA, Henderson WG, Cowper Ripley DC, Maciejewski ML, Vogel WB, Hutt E (2013) Improving hip fractures outcomes for COPD patients. COPD 10:11–19PubMedCrossRef
122.
Kirchgatterer A, Wenzl HH, Aschl G, Hinterreiter M, Stadler B, Hinterleitner TA, Petritsch W, Knoflach P (2002) Examination, prevention and treatment of osteoporosis in patients with inflammatory bowel disease: recommendations and reality. Acta Med Austriaca 29:120–123PubMedCrossRef
123.
Etzel JP, Larson MF, Anawalt BD, Collins J, Dominitz JA (2011) Assessment and management of low bone density in inflammatory bowel disease and performance of professional society guidelines. Inflamm Bowel Dis 17:2122–2129PubMedCrossRef
124.
Knopp-Sihota JA, Cummings GG, Newburn-Cook CV, Homik J, Voaklander D (2014) Dementia diagnosis and osteoporosis treatment propensity: a population-based nested case-control study. Geriatr Gerontol Int 14:121–129PubMedCrossRef
125.
Caplan L, Hines AE, Williams E, Prochazka AV, Saag KG, Cunningham F, Hutt E (2011) An observational study of glucocorticoid-induced osteoporosis prophylaxis in a national cohort of male veterans with rheumatoid arthritis. Osteoporos Int 22:305–315PubMedCrossRef
126.
Romme EA, Geusens P, Lems WF, Rutten EP, Smeenk FW, van den Bergh JP, van Hal PT, Wouters EF (2015) Fracture prevention in COPD patients; a clinical 5-step approach. Respir Res 16:32PubMedPubMedCentralCrossRef
127.
British Society of Gastroenterology (2007) Guidelines for osteoporosis in inflammatory bowel disease and coeliac disease
128.
Duru N, van der Goes MC, Jacobs JW et al (2013) EULAR evidence-based and consensus-based recommendations on the management of medium to high-dose glucocorticoid therapy in rheumatic diseases. Ann Rheum Dis 72:1905–1913PubMedCrossRef
129.
Seeman E, Compston J, Adachi J, Brandi ML, Cooper C, Dawson-Hughes B, Jonsson B, Pols H, Cramer JA (2007) Non-compliance: the Achilles’ heel of anti-fracture efficacy. Osteoporos Int 18:711–719PubMedCrossRef
130.
Hiligsmann M, Salas M, Hughes DA, Manias E, Gwadry-Sridhar FH, Linck P, Cowell W (2013) Interventions to improve osteoporosis medication adherence and persistence: a systematic review and literature appraisal by the ISPOR Medication Adherence & Persistence Special Interest Group. Osteoporos Int 24:2907–2918PubMedCrossRef
131.
Boudou L, Gerbay B, Chopin F, Ollagnier E, Collet P, Thomas T (2011) Management of osteoporosis in fracture liaison service associated with long-term adherence to treatment. Osteoporos Int 22:2099–2106PubMedCrossRef
132.
Dehamchia-Rehailia N, Ursu D, Henry-Desailly I, Fardellone P, Paccou J (2014) Secondary prevention of osteoporotic fractures: evaluation of the Amiens University Hospital’s fracture liaison service between January 2010 and December 2011. Osteoporos Int 25:2409–2416PubMedCrossRef
133.
Ganda K, Schaffer A, Pearson S, Seibel MJ (2014) Compliance and persistence to oral bisphosphonate therapy following initiation within a secondary fracture prevention program: a randomised controlled trial of specialist vs. non-specialist management. Osteoporos Int 25:1345–1355PubMedCrossRef
134.
Feldstein AC, Schneider J, Smith DH, Vollmer WM, Rix M, Glauber H, Boardman DL, Herson M (2008) Harnessing stakeholder perspectives to improve the care of osteoporosis after a fracture. Osteoporos Int 19:1527–1540PubMedCrossRef
135.
Sujic R, Gignac MA, Cockerill R, Beaton DE (2013) Factors predictive of the perceived osteoporosis-fracture link in fragility fracture patients. Maturitas 76:179–184PubMedCrossRef
136.
Siris ES, Gehlbach S, Adachi JD et al (2011) Failure to perceive increased risk of fracture in women 55 years and older: the Global Longitudinal Study of Osteoporosis in Women (GLOW). Osteoporos Int 22:27–35PubMedCrossRef
137.
138.
National Committee for Quality Assurance (2015) The State of Health Care Quality 2015. Washington D.C
139.
Black DM, Rosen CJ (2016) Clinical practice: postmenopausal osteoporosis. N Engl J Med 374:254–262PubMedCrossRef
140.
Khan AA, Morrison A, Hanley DA et al (2015) Diagnosis and management of osteonecrosis of the jaw: a systematic review and international consensus. J Bone Miner Res Off J Am Soc Bone Miner Res 30:3–23CrossRef
141.
Kim DH, Rogers JR, Fulchino LA, Kim CA, Solomon DH, Kim SC (2015) Bisphosphonates and risk of cardiovascular events: a meta-analysis. PLoS One 10:e0122646PubMedPubMedCentralCrossRef
142.
Dell RM, Adams AL, Greene DF, Funahashi TT, Silverman SL, Eisemon EO, Zhou H, Burchette RJ, Ott SM (2012) Incidence of atypical nontraumatic diaphyseal fractures of the femur. J Bone Miner Res Off J Am Soc Bone Miner Res 27:2544–2550CrossRef
143.
Kim SC, Kim DH, Mogun H, Eddings W, Polinski JM, Franklin JM, Solomon DH (2016) Impact of the US food and drug administration’s safety-related announcements on the use of bisphosphonates after hip fracture. J Bone Miner Res Off J Am Soc Bone Miner Res
144.
International Osteoporosis Foundation (2011) The Eastern European & Central Asian Regional Audit: epidemiology, costs & burden of osteoporosis in 2010
145.
Kanis JA, Borgstrom F, Compston J, Dreinhofer K, Nolte E, Jonsson L, Lems WF, McCloskey EV, Rizzoli R, Stenmark J (2013) SCOPE: a scorecard for osteoporosis in Europe. Arch Osteoporos 8:144PubMedPubMedCentralCrossRef
146.
Kanis JA, Johnell O (2005) Requirements for DXA for the management of osteoporosis in Europe. Osteoporos Int 16:229–238PubMedCrossRef
147.
International Osteoporosis Foundation (2012) The Latin America Regional Audit: epidemiology, costs & burden of osteoporosis in 2012. Nyon, Switzerland
148.
International Osteoporosis Foundation (2011) The Middle East & Africa Regional Audit: epidemiology, costs & burden of osteoporosis in 2011
149.
150.
Cooper C, Mitchell P, Kanis JA (2011) Breaking the fragility fracture cycle. Osteoporos Int 22:2049–2050PubMedCrossRef
151.
Zerbini CA, Szejnfeld VL, Abergaria BH, McCloskey EV, Johansson H, Kanis JA (2015) Incidence of hip fracture in Brazil and the development of a FRAX model. Arch Osteoporos 10:224PubMedCrossRef
152.
Lesnyak O, Ershova O, Belova K et al (2012) Epidemiology of fracture in the Russian Federation and the development of a FRAX model. Arch Osteoporos 7:67–73PubMedCrossRef
Metadata
Title
Mind the (treatment) gap: a global perspective on current and future strategies for prevention of fragility fractures
Authors
N. C. W. Harvey
E. V. McCloskey
P. J. Mitchell
B. Dawson-Hughes
D. D. Pierroz
J.-Y. Reginster
R. Rizzoli
C. Cooper
J. A. Kanis
Publication date
01-05-2017
Publisher
Springer London
Published in
Osteoporosis International / Issue 5/2017
Print ISSN: 0937-941X
Electronic ISSN: 1433-2965
DOI
https://doi.org/10.1007/s00198-016-3894-y

Other articles of this Issue 5/2017

Osteoporosis International 5/2017 Go to the issue

Original Article

Validity of height loss as a predictor for prevalent vertebral fractures, low bone mineral density, and vitamin D deficiency

Original Article

Skeletal effects of vitamin D deficiency among patients with primary hyperparathyroidism

Original Article

Bone mass loss is associated with systolic blood pressure in postmenopausal women with type 2 diabetes in Tibet: a retrospective cross-sectional study

Original Article

Cost-effectiveness of denosumab versus oral alendronate for elderly osteoporotic women in Japan

Review

Worldwide prevalence and incidence of osteoporotic vertebral fractures

Letter

Comments on Kamimura et al.: significant improvement of bone mineral density and bone turnover markers by denosumab therapy in bisphosphonate-unresponsive patients